An experimental vaccine for 20 types of influenza gives a strong immune memory to prevent the disease

New experiments on a comprehensive vaccine against different influenza strains that give people a strong immune memory to prevent disease, and protect people from different types to prevent future epidemics of influenza.

According to Reuters, the experimental vaccine offers broad protection against all subtypes of influenza virus A And B The 20 known viruses are in preliminary tests on mice and rodents, which could open a path to a universal influenza vaccine that may help prevent future pandemics, according to a recently published US study.

The two-dose vaccine uses the same mRNA technology (mRNA) Used in Corona vaccines developed by Pfizer Pfizer with BioNTech and modern Modern It delivers small lipid particles that contain instructions mRNA For the cells to make replicas of the so-called hemagglutinin proteins that appear on the surfaces of the influenza virus..

According to Reuters, the idea of ​​developing a universal flu vaccine here is to have a vaccine that gives people a basic level of immunological memory of the various influenza strains, so that there will be much fewer illnesses and deaths when the next influenza pandemic hits.

Unlike standard flu vaccines that deliver one or two copies of hemagglutinin, the experimental vaccine includes 20 different variants in hopes of getting the immune system to recognize any influenza virus it might encounter in the future, Scott Hensley, study leader and professor at the University of Pennsylvania, said in a statement..

In laboratory experiments, the immune systems of vaccinated animals recognized and defended the hemagglutinin proteins against 18 different strains of influenza A and two strains of influenza B..

The researchers confirmed that the vaccine reduced the signs of the disease and protected it from death, even when the rodents were exposed to a different type of influenza that was not found in the vaccine, adding that both Moderna had Modern and Pfizer Pfizer Flu vaccines mRNA In the final stages of human trials, GlaxoSmith is doing GSK and her partner CureVac testing a flu vaccine based on the technology mRNA In early stage human safety trials, these vaccines are designed to defend against only 4 strains of influenza that have been circulating recently but could theoretically be changed every year.

If he succeeds Influenza vaccine Even in human trials, it won’t necessarily prevent infection, and Hensley said the goal is to provide lasting protection against severe illness and death.

Allison Kelvin and Daryl Falzarano, of the University of Saskatchewan, Canada, explain in a commentary published with the study, that questions remain regarding how to judge efficacy and potential regulatory requirements for a vaccine against potential future viruses not currently in circulation.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.